The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...
A new drug application seeking the accelerated approval of dordaviprone forrecurrent for H3K27M-mutant diffuse glioma ...
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...
The Union Public Service Commission (UPSC) has extended the registration deadline for the National Defence Academy (NDA) and ...
The UPSC NDA & NA (I) 2025 exam is being held to fill 406 vacancies, while the CDS (I) 2025 exam will fill a total of 457 ...
UPSC has extended the NDA & CDS I 2025 registration deadline to 6 PM on 1 January 2025 due to technical issues. Candidates ...
Jagran Josh on MSN5d
NDA and CDS 1 Exam 2025 Registration Closing Today: Check online application process, fee details, and correction window informationThe correction window will be open between January 1 and January 7, in which candidates can modify their application forms by ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
Verastem Oncology announced that the FDA has accepted for review the New Drug Application, NDA, under the accelerated approval pathway for avutometinib, an ...
Chimerix (CMRX) confirms that the Company has submitted a New Drug Application with the U.S. Food and Drug Administration seeking accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback